NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments
- KOL Discussion of STRO-002 Data Event scheduled for December 3rd - Interim Phase 1 data from STRO-001 for patients with NHL will be presented at ASH - Milestone payment received from EMD Serono collaboration on MUC1-EGFR bispecific ADC - Honored as Best New Drug...
Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company today announced that it has been recognized as Best New Drug Developer at the World ADC Digital Awards, held...
Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
Updated Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression Conference Call Today Scheduled for 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 – Sutro...
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting
Ongoing Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression Conference Call Scheduled for Sept 9, 2020 at 5:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020...
Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
SOUTH SAN FRANCISCO, Calif., August 25, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing
Mr. Carlos Lugo promoted to Vice President of Quality and CMC Regulatory Operations Mr. Devendra Luhar promoted to Vice President of Manufacturing & Plant Operations SOUTH SAN FRANCISCO, Calif., August 11, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., August 10, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments
Encouraging STRO-002 Interim Phase 1 Clinical Data Presented at the AACR Virtual Meeting in April STRO-002 Preclinical Data Presented at 2020 AACR Virtual Annual Meeting II in June Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors STRO-001 Dose...
Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
Additionally, Sutro’s partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration’s pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1 SOUTH SAN FRANCISCO, Calif., June 22, 2020...
